WO2018021874A1 - Functional sanitary napkin - Google Patents

Functional sanitary napkin Download PDF

Info

Publication number
WO2018021874A1
WO2018021874A1 PCT/KR2017/008163 KR2017008163W WO2018021874A1 WO 2018021874 A1 WO2018021874 A1 WO 2018021874A1 KR 2017008163 W KR2017008163 W KR 2017008163W WO 2018021874 A1 WO2018021874 A1 WO 2018021874A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture
accession
nite
sanitary napkin
lactobacillus plantarum
Prior art date
Application number
PCT/KR2017/008163
Other languages
French (fr)
Korean (ko)
Inventor
김기태
Original Assignee
바이오제닉스코리아 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오제닉스코리아 주식회사 filed Critical 바이오제닉스코리아 주식회사
Publication of WO2018021874A1 publication Critical patent/WO2018021874A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47Sanitary towels, incontinence pads or napkins
    • A61F13/472Sanitary towels, incontinence pads or napkins specially adapted for female use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/84Accessories, not otherwise provided for, for absorbent pads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/84Accessories, not otherwise provided for, for absorbent pads
    • A61F13/8405Additives, e.g. for odour, disinfectant or pH control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/36Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F2013/16Sanitary towels; Means for supporting or fastening them
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41Anti-inflammatory agents, e.g. NSAIDs

Definitions

  • the present invention relates to a functional sanitary napkin, and more particularly, to a functional sanitary napkin having antibacterial, anti-inflammatory and anti-allergic properties, which can prevent infection, skin irritation, and eczema by pathogens.
  • the endometrium of a woman of childbearing age is periodically proliferated by hormones to prepare for implantation of the embryo. If the pregnancy does not occur, the endometrium is spontaneously dropped and this phenomenon is called menstruation or menstruation.
  • Fertility refers to the period during which the egg can ovulate and become pregnant. It refers to the period from the beginning of menarche to menopause. The average menopause age is about 13 years old and the average menopause age is about 50 years old. Menstrual cycles can be divided into follicular and luteal phases, and ovulation occurs during the transition from follicular phases to luteal phases.
  • the sanitary napkin is used to prevent leakage of menstrual blood and secretion during the menstrual period, as shown in Figure 1, the sanitary napkin is generally to prevent the leakage of the internal sheet 100, such as menstrual blood, and menstrual blood
  • the outer sheet 300 and the absorbent member 200 positioned between the inner sheet 100 and the outer sheet 300 to absorb the menstrual blood, etc., and to absorb the menstrual blood.
  • the outer sheet 300 may be provided with an adhesive means such as an adhesive material.
  • sanitary napkins may cause skin irritation, skin eczema, and skin irritation due to secretions such as menstrual blood, and during menstruation, mental and physical resistance is weakened. Therefore, human infections such as skin infections and vaginal infections are caused by bacterial growth such as pathogens. May cause problems.
  • the present invention confirms that lactic acid bacteria cultures such as Lactobacillus plantarum nF1 disclosed in Korean Patent Registration No. 10-1583018 and Korean Patent Application Publication No. 2014-0140387 have anti-allergic and anti-inflammatory activity as well as antibacterial activity.
  • a functional sanitary napkin is disclosed that can prevent human infection by bacteria such as pathogens and prevent skin irritation.
  • An object of the present invention is to provide a functional sanitary napkin that can prevent infection and skin irritation caused by pathogens.
  • the functional sanitary napkin of the present invention comprises (i) an inner sheet and an outer sheet, and (ii) an absorbent member interposed therebetween, wherein the inner sheet and / or absorbent member is Lactobacillus plantarum. It is characterized by impregnating a lactic acid bacteria culture such as nF1 or a solution containing the same.
  • the functional sanitary napkin of the present invention exhibits anti-inflammatory, anti-allergic, as well as antibacterial, Due to such antimicrobial properties, it has the effect of preventing human infection from bacteria such as pathogens, and also has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.
  • lactic acid bacteria cultures such as Lactobacillus plantarum nF1, Bacillus subtilis , Staphylococcus aureus (except for some microorganisms of some cultures) Staphylococcus aureus ), Staphylococcus mutans ( Strptococcus) mutans ), Escherichia coli ) and Gardnerella vaginalis , which have an overall antimicrobial activity and produce nitric oxide (NO) in macrophages, a major cell in the inflammatory response stimulated with the inflammatory substance lipopolysacharide (LPS).
  • NO nitric oxide
  • LPS lipopolysacharide
  • rat cell line RBL-2H3 rat basophilic leukemia
  • IgE and antigen DNP-BSA
  • the gardnerella pannalis is an anaerobic bacterium known as a major causative agent of bacterial vaginosis found in more than 98% of women with bacterial vaginosis (Korean Journal of Obstetrics and Gynecology 36 (6): 837-46, 1993). Bacterial vaginosis caused by is caused to increase the pH in the vagina to 5.0 or more, exhibits peculiar odors, pruritus and other symptoms, and is characterized by increased vaginal discharge (Am J Obstet Gynecol. 158 (4): 819-). 28, 1988).
  • mast cells which are the major mediators of allergic reactions, contain beta-hexosaminidase in addition to histamine, and beta-hexosaminidase is released together with histamine when mast cells degranulate.
  • Beta-hexosaminidase is known as an indicator for assessing degranulation inhibitory activity, antihistamine activity and anti-allergic activity of mast cells (Immunol., 123: 1445-1450, 1970); J Korean Soc Appl Biol Chem. 48 (4): 315-321, 2005).
  • lactic acid bacteria cultures such as Lactobacillus plantarum nF1 prevent bacterial vaginosis caused by infections such as Gardnerella pannalis through antibacterial activity, anti-inflammatory activity and anti-allergic activity. It can be said that it can alleviate skin inflammation.
  • lactic acid bacteria refers to Lactobacillus plantarum nF1 (Accession No. NITE P-1462), Lactobacillus plantarum SNK12 (Accession No .: NITE P-1445), Lactobacillus plantarum KH3 (Accession No. NITE AP) -1476), Enterococcus faecalis KH2 (Accession No. NITE P-1444), and / or Lactobacillus brevis (Accession No. FERP BP-4693) ("Labre”), which are lactobacillus products manufactured by an independent Japanese corporation. It is a microorganism entrusted to the National Institute of Technology and Evaluation (NITE; International Patent Organism Depositary, IPOD) of the Evaluation Technology Infrastructure Organization. See 2014-0140387. These patent documents are all considered part of this specification.
  • lactic acid bacteria culture is obtained by inoculating and culturing lactic acid bacteria with a suitable medium in which lactic acid bacteria can grow, such as MRS Broth.
  • a suitable medium in which lactic acid bacteria can grow such as MRS Broth.
  • the culture itself and its culture are concentrated under reduced pressure and / or lyophilized.
  • the culture itself or the processed product thereof having a lower alcohol having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate Suspensions or solutions suspended or dissolved in butyl acetate, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, the culture Meaning extracting itself or its processed product with the solvents listed above, and processing the extract into liquid or powder form by concentration under reduced pressure and / or lyophilization. .
  • a lower alcohol having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate
  • dispersion medium or the solvent after the impregnation in a manner known in the art such as a hot air drying method.
  • a hot air drying method In order to stabilize the impregnation of the lactic acid bacteria culture and to prevent the dispersion medium or the solvent may be toxic to the human body such as skin irritation. For this reason, preferred dispersion mediums or solvents are water, ethanol or a mixed solvent thereof.
  • the functional sanitary napkin of the present invention may further include an auxiliary absorbing member, and when the auxiliary absorbing member is further included, an end portion may be further formed in the endothelial sheet so that the auxiliary absorbing member may be detachably inserted.
  • the functional sanitary napkin of the present invention is an inner sheet, an absorbent member, an outer sheet, and an optional absorbent member which is an optional absorbent member, which is a component of a conventional sanitary napkin, and their materials and configurations are known in the art, and related details are as follows. See embodiments of.
  • a functional sanitary napkin impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1 exhibiting antibacterial activity, anti-inflammatory activity, anti-allergic activity and the like can be provided.
  • the functional sanitary napkin of the present invention is impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1, which exhibits antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., and thus has an effect of preventing human infection from bacteria such as pathogens. It has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.
  • a lactic acid bacteria culture such as Lactobacillus plantarum nF1
  • Lactobacillus plantarum nF1 which exhibits antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc.
  • FIG. 1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention.
  • FIG. 2 is an exploded perspective view of the sanitary napkin according to the preferred embodiment of the present invention.
  • FIG. 3 is a perspective view of a sanitary napkin according to another preferred embodiment of the present invention.
  • FIG. 1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention
  • Figure 2 is an exploded perspective view of the sanitary napkin according to a preferred embodiment of the present invention.
  • the antibacterial sanitary napkin is largely composed of an inner sheet 100 and an outer sheet 300 and an absorbing member 200 disposed therebetween.
  • the inner sheet 100 has a material and structure through which secretion, such as menstrual blood, can pass, and may be specifically composed of one or more layers of fabrics or nonwoven fabrics.
  • the fibers constituting the woven or nonwoven fabric can be used both synthetic fibers and natural fibers without particular limitation, if synthetic fibers, nylon, polyvinyl alcohol (PVA) fibers, polyester fibers, polyacrylic fibers, polyamide fibers, polyurethane Fibers, polyacrylonitrile fibers, polypropylene fibers, polyethylene fibers and the like can all be used without limitation, and if natural fibers, cotton fibers, seed fibers such as Coier, leaf vein fibers such as manila hemp and sisal hemp, flax , Bast fibers such as ramie grass, hemp, wool fibers such as wool, goat wool, silk fibers such as gaze dog, and night sleep dog can be used without limitation.
  • a fabric made of natural fibers such as cotton fabrics.
  • the inner sheet 100 is a member in contact with the human body may be caused skin irritation, skin eczema, skin inflammation, etc. by secretions such as menstrual blood absorbed in the inner sheet 100 or penetrating the inner sheet 100, including pathogens Since various bacteria can proliferate, in order to prevent such skin irritation and suppress the growth of various bacteria, Lactobacillus has been confirmed antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., as confirmed in the experimental example below Lactobacillus cultures such as plantarum nF1, its extracts, its concentrates, its dilutions, or its suspensions or solutions using a dispersion medium or a solvent as water or ethanol are impregnated into the inner sheet 100 for antibacterial function, You can have anti-inflammatory activity, anti-allergy, etc.
  • the impregnation may be made by immersing the inner sheet 100 in a diluent of a lactic acid bacterium culture such as Lactobacillus plantarum nF1 at room temperature, preferably for at least 12 hours, more preferably at least 24 hours.
  • a lactic acid bacterium culture such as Lactobacillus plantarum nF1
  • the lactic acid bacteria cultures such as Lactobacillus plantarum nF1 which are impregnated, are stabilized and hot air dried at a temperature ranging from 40 ° C. to 50 ° C., for example, to remove solvents that may cause irritation or toxicity to the skin. It may be desirable to.
  • Such natural materials include plant extracts having anti-inflammatory activity, anti-allergic activity, or both, specifically, Styrax japonica extract, Chloranthus japonicus ) extract, Podocarpus macrophyllus extract, Distylium racemosom extract, Rhododendron mucronulatum , Empetrum nigrum extract, Marsilea quadrifolia extract, Potentilla discolor extract, Gleichenia japonica extract, Cimicifuga acerina extract, Citrus sunki rind extract, Sceptridium ternatum extract and Korthalsella japonica extract are among such plant extracts.
  • endothelial sheet When the extract is impregnated, endothelial sheet by immersing the endothelial sheet 100 in these natural product extracts at a constant time, such as 12 hours or 24 hours or more at room temperature, using an extract in the extract state with or without filtration.
  • Functionality such as skin irritation relief can be imparted to (100).
  • the extraction solvent which may have skin irritation may be a solvent remaining in the endothelial sheet 100 when impregnated, and the residual solvent may cause skin irritation, so that the impregnated inner sheet 100 may be hot air dried.
  • Drying is carried out in a manner known in the art to remove residual solvents, or when using an extract obtained with an extraction solvent other than water and ethanol, it is concentrated in the art after extraction, freeze drying, vacuum drying, hot air drying, spray drying, etc. It is also possible to avoid the skin irritation problem caused by the extraction solvent by removing the extraction solvent in a manner known in the present invention to obtain a powdered extract and dissolving the powdered extract in water or ethanol, especially ethanol.
  • the absorbent member 200 is to absorb secretions such as menstrual blood, so that the absorbency and water retention should be excellent, so that the absorbent member 200 may consider cotton fiber or wool, goat's wool, etc. It can be made of the hair wool fiber, etc. in the form of cotton and the composition of the nonwoven fabric and the like.
  • the content may be a polymer absorbent such as sodium polyacrylate, which has been conventionally used in sanitary napkins.
  • Sodium polyacrylate is a material known in the art to have an absorption ability to absorb about 200 times its weight.
  • the absorbing member 200 is a member for absorbing secretions such as menstrual blood, bacteria such as pathogens may proliferate. Therefore, in order to suppress this, it is preferable to impregnate the culture of lactic acid bacteria such as Lactobacillus plantarum nF1, such as the antibacterial activity is confirmed, such as the inner sheet 100 to have an antibacterial function.
  • lactic acid bacteria such as Lactobacillus plantarum nF1
  • the antibacterial activity is confirmed, such as the inner sheet 100 to have an antibacterial function.
  • the outer sheet 300 is located on the outside of the absorbent member 200. Since the outer sheet 300 is a member in contact with the underwear without touching the skin, it should be able to prevent the leakage of secretion such as menstrual blood. It is made of a waterproof material such as polyethylene film. In addition, the outer surface of the outer sheet 300 can be attached to and fixed to the underwear by forming an adhesive member with an adhesive and release paper.
  • the adsorption member 200 is finally placed between the inner sheet 100 and the outer sheet 300, and the periphery of the inner sheet 100 and the outer sheet 300 is stitched, ultrasonically fused or heated. It is made by bonding by fusion.
  • the functional sanitary napkin of the present invention may further comprise an auxiliary adsorption member 400 for further use in the case of a large amount of secretion, such as menstrual blood, depending on the woman as shown in FIG.
  • the auxiliary adsorption member 400 may be made of cotton fibers, wool fibers such as wool, goat wool, or the like in the form of cotton, or a polymer absorbent such as sodium polyacrylate.
  • the outer shell may be made of a nonwoven fabric or the like.
  • the inner sheet 100 may be inserted to detach the auxiliary adsorption member 100 by forming a cutout 101.
  • auxiliary adsorption member 400 it may be preferable to impregnate the lactic acid bacteria culture such as Lactobacillus plantarum nF1 so that the auxiliary adsorption member 400 also has antibacterial properties.
  • the functional sanitary napkin of the present invention has been described based on the inner sheet 100, the absorbent member 200, and the outer sheet 300, which are basic components, but the functional sanitary napkin of the present invention is the inner sheet 100 and / or absorbent.
  • the member 200 is impregnated with a culture of lactic acid bacteria such as Lactobacillus plantarum nF1 to have antimicrobial activity, anti-inflammatory activity, anti-allergy, and the like. It is to be understood that added and modified sanitary napkins are also included in the scope of the present invention.
  • Lactobacillus was inoculated at MRS (DeMan, Rogosa, and Sharpe) broth (Difco Lactobacilli MRS Broth, Japan Becton, Dickinson & Co.) at an initial cell concentration of 1 ⁇ 10 4 cfu / mL, and Lactobacillus plantarum nF1 (Accession No. NITE P-1462) ("nF1"), Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445) (“SNK12”), Lactobacillus plantarum KH3 (Accession Number NITE AP-1476) ("KH3" ) At 32 ° C., 37 ° C.
  • KH2 Enterococcus faecalis KH2 (Accession No. NITE P-1444) (“KH2”), and 31 to 32 for Lactobacillus brevis (Accession No. FERP BP-4693) (“Labre”).
  • C. Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848) (“CF4”) was incubated at 30 ° C. for 2 days.
  • the culture was sterilized at 121 ° C. for 20 minutes using a sterilizer, concentrated under reduced pressure and lyophilized, and used for experiments while refrigerated.
  • Antimicrobial activity was measured by plate medium diffusion method (Food. Chem. Toxicol. 40 (4): 535-543, 2002).
  • the disk to be used for the experiment was dissolved in ethanol at a concentration of 1 mg / ml of the sample (culture of ⁇ Experimental Example 1-1>), and then slowly absorbed the sample solution into the disk (Whatman No. 5), and then completely removed the solvent.
  • the prepared disk was adhered to the plate medium plated with each test bacteria and incubated at the incubation temperature of the following [Table 1], and then the size (mm) of growth zones (clear zone) formed around the disk was measured. The results are shown in [Table 2].
  • Anti-inflammatory activity was evaluated using a cell model in which RAW264.7 cells, a mouse macrophage line, were stimulated with Lipopolysacharide (LPS). Specifically, the mouse macrophage cells were dispensed in a 48 well plate with a cell number of 5 ⁇ 10 4 cells / well and incubated for 24 hours at 37 ° C. and 5% CO 2 . 100 ⁇ g / ml sample and 1 ⁇ g / ml LPS were co-treated and incubated for 24 hours.
  • LPS Lipopolysacharide
  • Cell viability was measured by the MTT method. Specifically, the remaining medium in the 48 well plate was removed, and 100 ⁇ l of serum free medium containing 10% of 5 mg / ml MTT solution was added to each well in 37 ° C. and 5% CO 2 incubator, followed by reaction for 2 hours. Removed and dissolved DMSO in 100 ⁇ l / well for 15 minutes in the shaker and measured the absorbance at 540nm using ELlSA reader to determine the cell viability. The results are shown in Table 3 together.
  • Anti-allergic activity was assessed by ⁇ -hexosaminidase assay.
  • a rat basophilic leukemia cell line RBL-2H3 cell line was dispensed into 2 wells at 24 ⁇ plates at 2 ⁇ 10 5 cells / well and treated with 0.5 ⁇ g / ml mouse monoclonal IgE at 37 ° C., 5%. Cells were sensitized by incubating overnight in CO 2 conditions.
  • the sensitized cells were washed twice with siraganian buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 40 mM NaOH, pH 7.2) and 160 ⁇ l PIPES buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 0.4 mM MgCl 2 , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA) was added and incubated at 37 ° C. for 10 minutes.
  • siraganian buffer 25 mM PIPES, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA
  • DNP-HSA Dinitrophenyl-Human Serum Albumin, 1 ⁇ g / ml
  • 20 ⁇ l of the supernatant of the reactants was put into a 96 well plate, and 20 ⁇ m of substrate 1 mM P-nitrophenyl-acetyl- ⁇ -D-glucosamide was added and reacted at 37 ° C. for 1 hour.
  • a stop solution (0.1 M NaHCO 3 , 0.1 M Na 2 CO 3 ) was added thereto, and the reaction was terminated.
  • the absorbance was measured using an ELISA reader at a wavelength of 405 nm. The results are shown in [Table 4] as a percentage compared to the sample untreated group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention discloses a functional sanitary napkin which is impregnated with a culture of lactic acid bacteria, such as Lactobacillus plantarum nF1, exhibiting antibacterial, anti-inflammatory, and anti-allergic activities, thereby having the effect of preventing pathogens such as bacteria from infecting the human body and secretions such as menstrual blood from causing skin irritation, skin eczema, and skin inflammation.

Description

기능성 생리대Functional sanitary napkin
본 발명은 기능성 생리대에 관한 것으로, 구체적으로는 항균성, 항염증성 및 항알러지성을 가져 병원균에 의한 감염, 피부 자극, 피부 습진 등을 예방할 수 있는 기능성 생리대에 관한 것이다.The present invention relates to a functional sanitary napkin, and more particularly, to a functional sanitary napkin having antibacterial, anti-inflammatory and anti-allergic properties, which can prevent infection, skin irritation, and eczema by pathogens.
가임기 여성의 자궁내막은 주기적으로 분비된 호르몬에 의하여 증식하여 배아의 착상을 준비하는데 임신이 되지 않으면 자궁내막이 저절로 탈락되며 이 현상을 월경 즉 생리라고 한다. 가임기는 난자가 배란이 되어 임신이 가능한 기간을 뜻하는 것으로 초경이 시작되는 나이부터 폐경이 될 때까지를 일컬으며, 평균 초경 연령은 13세 정도이고 평균 폐경 연령은 약 50세 전후이다. 생리 주기는 난포기, 황체기로 나눌 수 있고, 난포기에서 황체기로 넘어가는 시기에 배란이 일어난다. 난포기에 난소에서 여성호르몬(에스트로겐)의 분비가 증가하고, 이에 따라 생리는 멈추고 자궁의 내막은 증식하여 두꺼워지기 시작한다. 동시에 한쪽 난소에서 난자가 성숙되어 생리 주기가 28일인 경우, 생리 시작 14일 전후로 배란이 된다. 배란 이후 난소에서는 황체호르몬(프로게스테론) 분비가 증가하는데 자궁내막 착상에 대한 준비를 하도록 도와준다. 임신이 되지 않으면 28일째 정도에 자궁내막이 떨어져 나온다. 정상적인 생리 주기는 연속하는 두 번의 생리의 시작일 사이의 간격으로 통상 21~35일(평균 28일)이고, 3~7일간 지속되며, 생리혈은 여성에 따라 다르지만 평균 35㎖이며 10~80㎖까지를 정상으로 본다.The endometrium of a woman of childbearing age is periodically proliferated by hormones to prepare for implantation of the embryo. If the pregnancy does not occur, the endometrium is spontaneously dropped and this phenomenon is called menstruation or menstruation. Fertility refers to the period during which the egg can ovulate and become pregnant. It refers to the period from the beginning of menarche to menopause. The average menopause age is about 13 years old and the average menopause age is about 50 years old. Menstrual cycles can be divided into follicular and luteal phases, and ovulation occurs during the transition from follicular phases to luteal phases. In the follicle, the secretion of female hormone (estrogen) increases in the ovary, which stops menstruation and the lining of the uterus proliferates and begins to thicken. At the same time, when the egg matures in one ovary and the menstrual cycle is 28 days, ovulation occurs about 14 days before the start of menstruation. After ovulation, luteal hormone (progesterone) secretion increases in the ovaries, which helps prepare for endometrial implantation. If you are not pregnant, the endometrium will fall off on day 28. Normal menstrual cycles are usually between 21 and 35 days (28 days on average), lasting 3 to 7 days at intervals between the start of two consecutive menstruation periods. Looks normal.
생리 기간 중 생리혈 등 분비물의 누출을 방지하기 위하여 생리대를 사용하게 되는데, 생리대는 도 1에 도시된 바와 같이 일반적으로 생리혈 등이 투과될 수 있는 내부시트(100)와, 생리혈 등의 누수를 방지하기 위하여 내부시트(100) 반대편에 위치하는 외부시트(300)와, 내부시트(100)와 외부시트(300) 사이에 게재되어 생리혈 등을 흡수하기 위한 흡수부재(200)를 기본 구성으로 하며, 이외에 외부시트(300) 등에 접착재 등 속옷과의 접착수단이 구비될 수 있다. The sanitary napkin is used to prevent leakage of menstrual blood and secretion during the menstrual period, as shown in Figure 1, the sanitary napkin is generally to prevent the leakage of the internal sheet 100, such as menstrual blood, and menstrual blood In order to have the outer sheet 300 and the absorbent member 200 positioned between the inner sheet 100 and the outer sheet 300 to absorb the menstrual blood, etc., and to absorb the menstrual blood. The outer sheet 300 may be provided with an adhesive means such as an adhesive material.
그런데 생리대는 생리혈 등 분비물에 의해 피부 자극, 피부 습진, 피부 염증 등이 발생할 수 있고 생리 시에는 정신적·육체적으로 병원균의 저항력이 약해진 상태이므로 병원균 등의 세균 증식에 의하여 피부 감염, 질 감염 등 인체 감염의 문제가 발생할 수 있다. However, sanitary napkins may cause skin irritation, skin eczema, and skin irritation due to secretions such as menstrual blood, and during menstruation, mental and physical resistance is weakened. Therefore, human infections such as skin infections and vaginal infections are caused by bacterial growth such as pathogens. May cause problems.
본 발명은 한국 등록특허 제10-1583018호와 한국 공개특허 제2014-0140387호가 개시하는 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등이 항균 활성과 더불어 항알러지 활성, 항염증 활성을 가짐을 확인하고 이를 이용한, 병원균 등의 세균에 의한 인체 감염 등을 예방할 수 있고 더불어 피부 자극 등을 예방할 수 있는 기능성 생리대를 개시한다. The present invention confirms that lactic acid bacteria cultures such as Lactobacillus plantarum nF1 disclosed in Korean Patent Registration No. 10-1583018 and Korean Patent Application Publication No. 2014-0140387 have anti-allergic and anti-inflammatory activity as well as antibacterial activity. A functional sanitary napkin is disclosed that can prevent human infection by bacteria such as pathogens and prevent skin irritation.
본 발명의 목적은 병원균 등에 의한 감염과 피부 자극 등을 예방할 수 있는 기능성 생리대를 제공하는 데 있다.An object of the present invention is to provide a functional sanitary napkin that can prevent infection and skin irritation caused by pathogens.
본 발명의 다른 목적이나 구체적인 목적은 이하에서 제시될 것이다.Other and specific objects of the present invention will be presented below.
본 발명의 기능성 생리대는 (i) 주변부가 서로 접합된 내부시트와 외부시트 및 (ii) 그 사이에 게재된 흡수부재를 포함하여 구성되되, 상기 내부시트 및/또는 흡수부재는 락토바실러스 플란타럼 nF1 등의 유산균 배양물이나 그것을 포함하는 용액이 함침된 것을 특징으로 한다. The functional sanitary napkin of the present invention comprises (i) an inner sheet and an outer sheet, and (ii) an absorbent member interposed therebetween, wherein the inner sheet and / or absorbent member is Lactobacillus plantarum. It is characterized by impregnating a lactic acid bacteria culture such as nF1 or a solution containing the same.
이와 같은 구성을 가짐으로써 즉, 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등이 내부시트 및/또는 흡수부재에 함침됨으로써, 본 발명의 기능성 생리대는 항균성과 더불어 항염증성, 항알러지성을 나타나며, 이러한 항균성 등으로 인하여 병원균 등의 세균에 인체 감염을 예방할 수 있는 효과를 가지고 또한 생리혈 등 분비물에 의한 피부 자극, 피부 습진, 피부 염증 등을 예방할 수 있는 효과를 가진다. By having such a structure, that is, lactic acid bacteria culture such as Lactobacillus plantarum nF1 is impregnated into the inner sheet and / or absorbent member, the functional sanitary napkin of the present invention exhibits anti-inflammatory, anti-allergic, as well as antibacterial, Due to such antimicrobial properties, it has the effect of preventing human infection from bacteria such as pathogens, and also has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.
아래의 실험예에서 확인되듯이, 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등은 일부 배양물의 일부 미생물에 대한 경우를 제외하고 바실러스 섭틸러스(Bacillus subtilis), 스타필로코쿠스 아우레우스(Staphylococcus aureus), 스타필로코쿠스 뮤탄스(Strptococcus mutans), 대장균(Escherichia coli), 가드네렐라 바지날리스(Gardnerella vaginalis) 등에 대해 전반적인 항균 활성을 나타내며, 염증 유발 물질인 LPS(Lipopolysacharide)로 자극된 염증 반응의 주요 세포인 대식세포에서 산화질소(NO, nitric oxide) 생성 억제 활성을 나타낼 뿐만 아니라 알러지 반응의 개시 인자인 IgE 및 항원(DNP-BSA)으로 활성화된, 알러지 반응의 주요세포인 비만세포주 RBL-2H3(rat basophilic leukemia)에서 탈과립 억제 활성을 나타낸다. As can be seen in the experimental example below, lactic acid bacteria cultures such as Lactobacillus plantarum nF1, Bacillus subtilis , Staphylococcus aureus (except for some microorganisms of some cultures) Staphylococcus aureus ), Staphylococcus mutans ( Strptococcus) mutans ), Escherichia coli ) and Gardnerella vaginalis , which have an overall antimicrobial activity and produce nitric oxide (NO) in macrophages, a major cell in the inflammatory response stimulated with the inflammatory substance lipopolysacharide (LPS). In addition to showing inhibitory activity, it exhibits degranulation inhibitory activity in the rat cell line RBL-2H3 (rat basophilic leukemia), which is a major cell of the allergic reaction, activated with IgE and antigen (DNP-BSA), which are initiating factors of the allergic reaction.
상기 가드네렐라 바지날리스는 세균성 질증을 나타내는 여성의 98% 이상에서 발견되는 세균성 질증의 주요 원인균으로 알려진 혐기성 세균으로(대한산부인과학회지 36(6):837-46, 1993), 이 세균의 감염에 의한 세균성 질증은 질 내 pH를 5.0 이상으로 상승시키고, 특유의 악취, 소양감(pruritus) 등의 증상을 나타내며, 질의 분비물이 많아지는 특징을 가진다(Am J Obstet Gynecol. 158(4):819-28, 1988). The gardnerella pannalis is an anaerobic bacterium known as a major causative agent of bacterial vaginosis found in more than 98% of women with bacterial vaginosis (Korean Journal of Obstetrics and Gynecology 36 (6): 837-46, 1993). Bacterial vaginosis caused by is caused to increase the pH in the vagina to 5.0 or more, exhibits peculiar odors, pruritus and other symptoms, and is characterized by increased vaginal discharge (Am J Obstet Gynecol. 158 (4): 819-). 28, 1988).
또한 염증 반응시 iNOS(induced NOS)에 의해 과다 생성되는 NO는 수퍼옥사이드(superoxide)와 반응하여 퍼옥시니트라이트(peroxynitrite)를 형성하고 이는 강력한 산화제로 작용하여 세포에 손상을 입힘으로써 염증과 암을 포함한 다양한 병리적 과정에 관여한다고 보고되어 있어(Gupta SC et al., Exp Biol Med., 236:658-671, 2011; Riehemann et al., FEBS Lett., 442:89-94, 1999;Stamleret al., Science, 258:1898-1902, 1992), NO 생성을 억제하는 물질은 항염증제 후보물질로서 제안되고 있다(Karin M. et al., Cold Spring Harb Perspect Biol., 1, pp1-14, 2009). 또한 알러지 반응의 주요 매개세포인 비만세포는 그 과립 중에는 히스타민 외에 베타-헥소사미니다제(β-hexosaminidase)도 같이 저장되어 있어 비만세포가 탈과립을 일으키면 베타-헥소사미니다제가 히스타민과 함께 방출되므로, 베타-헥소사미니다제는 비만세포의 탈과립 억제 활성이나 항히스타민 활성, 항알러지 활성을 평가하기 위한 지표물질로서 알려져 있다(Immunol., 123:1445-1450, 1970); J Korean Soc Appl Biol Chem. 48(4):315-321, 2005)). In addition, NO, which is excessively produced by iNOS (induced NOS) during the inflammatory reaction, reacts with superoxide to form peroxynitrite, which acts as a powerful oxidant and damages cells, thereby causing inflammation and cancer. Has been reported to be involved in a variety of pathological processes including (Gupta SC et al., Exp Biol Med., 236: 658-671, 2011; Riehemann et al., FEBS Lett., 442: 89-94, 1999; Stame et al. , Science, 258: 1898-1902, 1992), substances that inhibit NO production have been proposed as anti-inflammatory candidates (Karin M. et al., Cold Spring Harb Perspect Biol., 1, pp 1-14, 2009) . In addition, mast cells, which are the major mediators of allergic reactions, contain beta-hexosaminidase in addition to histamine, and beta-hexosaminidase is released together with histamine when mast cells degranulate. Beta-hexosaminidase is known as an indicator for assessing degranulation inhibitory activity, antihistamine activity and anti-allergic activity of mast cells (Immunol., 123: 1445-1450, 1970); J Korean Soc Appl Biol Chem. 48 (4): 315-321, 2005).
따라서 아래의 실험예는 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등이 항균 활성, 항염 활성 및 항알러지 활성을 통해 가드네렐라 바지날리스 등의 감염에 의한 세균성 질증 등을 예방하고 피부 자극이나 피부 염증 등을 완화시킬 수 있음을 보여주는 것이라 할 수 있다.Therefore, the experimental example below shows that lactic acid bacteria cultures such as Lactobacillus plantarum nF1 prevent bacterial vaginosis caused by infections such as Gardnerella pannalis through antibacterial activity, anti-inflammatory activity and anti-allergic activity. It can be said that it can alleviate skin inflammation.
본 명세서에서, "유산균"은 락토바실러스 플란타럼 nF1(기탁번호 NITE P-1462), 락토바실러스 플란타럼 SNK12(기탁번호: NITE P-1445), 락토바실러스 플란타룸 KH3(기탁번호 NITE AP-1476), 엔테로코커스 패칼리스 KH2(수탁번호 NITE P-1444), 및/또는 락토바실러스 브레비스(수탁번호 FERP BP-4693)("Labre")를 의미하는데, 이들 유산균은 일본 독립행정법인인 제품평가기술기반기구의 특허미생물기탁센터(National Institute of Technology and Evaluation, NITE; International Patent Organism Depositary, IPOD)에 수탁되어 있는 미생물로서 그 균학적 특성 등에 대해서는 한국 등록특허 제10-1583018호와 한국 공개특허 제2014-0140387호를 참조할 수 있다. 이들 특허 문헌은 모두 본 명세서의 일부로서 간주 된다.As used herein, "lactic acid bacteria" refers to Lactobacillus plantarum nF1 (Accession No. NITE P-1462), Lactobacillus plantarum SNK12 (Accession No .: NITE P-1445), Lactobacillus plantarum KH3 (Accession No. NITE AP) -1476), Enterococcus faecalis KH2 (Accession No. NITE P-1444), and / or Lactobacillus brevis (Accession No. FERP BP-4693) ("Labre"), which are lactobacillus products manufactured by an independent Japanese corporation. It is a microorganism entrusted to the National Institute of Technology and Evaluation (NITE; International Patent Organism Depositary, IPOD) of the Evaluation Technology Infrastructure Organization. See 2014-0140387. These patent documents are all considered part of this specification.
또 본 명세서에서, "유산균 배양물"은 유산균을, 유산균이 생육할 수 있는 적정 배지, 예컨대 MRS Broth 등에 접종하고 배양하여 얻어진 것으로, 그 배양물 자체, 그 배양물을 감압농축 및/또는 동결건조시켜 액상 또는 분말 상으로 가공한 것, 그 배양물 자체나 그 가공물을 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급 알콜, 메틸렌클로라이드, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, N, N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합 용매에 현탁시키거나 용해시킨 현탁액이나 용액, 상기 배양물 자체나 그 가공물을 상기 열거된 용매로 추출한 것, 그리고 그 추출물을 감압농축 및/또는 동결건조시켜 액상 또는 분말상으로 가공한 것을 포함하는 의미이다. 여기서 현탁액이나 용액, 추출액 등을 함침에 사용할 경우, 함침 후에는 분산매나 용매를 열풍건조 방식 등 당업계에 공지된 방식으로 제거하는 것이 바람직하다. 그것은 유산균 배양물의 함침을 안정화시킴과 함께 상기 분산매나 용매가 피부 자극성 등 인체에 독성을 미칠 수 있어 이를 예방하기 위한 것이다. 이러한 이유에서 바람직한 분산매나 용매는 물, 에탄올 또는 이들의 혼합 용매이다. In the present specification, "lactic acid bacteria culture" is obtained by inoculating and culturing lactic acid bacteria with a suitable medium in which lactic acid bacteria can grow, such as MRS Broth. The culture itself and its culture are concentrated under reduced pressure and / or lyophilized. Processed into liquid or powder form, the culture itself or the processed product thereof having a lower alcohol having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate Suspensions or solutions suspended or dissolved in butyl acetate, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, the culture Meaning extracting itself or its processed product with the solvents listed above, and processing the extract into liquid or powder form by concentration under reduced pressure and / or lyophilization. . In the case where a suspension, a solution, an extract, or the like is used for impregnation, it is preferable to remove the dispersion medium or the solvent after the impregnation in a manner known in the art such as a hot air drying method. In order to stabilize the impregnation of the lactic acid bacteria culture and to prevent the dispersion medium or the solvent may be toxic to the human body such as skin irritation. For this reason, preferred dispersion mediums or solvents are water, ethanol or a mixed solvent thereof.
본 발명의 기능성 생리대에는 보조 흡수부재가 더 포함될 수 있으며, 보조 흡수부재가 더 포함될 경우, 내피시트에는 이 보조 흡수부재가 탈착적으로 삽입될 수 있도록 절개부가 더 형성될 수 있다.The functional sanitary napkin of the present invention may further include an auxiliary absorbing member, and when the auxiliary absorbing member is further included, an end portion may be further formed in the endothelial sheet so that the auxiliary absorbing member may be detachably inserted.
본 발명의 기능성 생리대는 내부시트, 흡수부재, 외부시트 그리고 선택적 부재인 보조 흡수부재 등은 통상적인 생리대의 구성요이며, 그것들의 재질, 구성 등은 당업계에 공지되어 있고, 관련된 구체적인 사항은 아래의 실시예를 참조할 수 있다.The functional sanitary napkin of the present invention is an inner sheet, an absorbent member, an outer sheet, and an optional absorbent member which is an optional absorbent member, which is a component of a conventional sanitary napkin, and their materials and configurations are known in the art, and related details are as follows. See embodiments of.
전술한 바와 같이, 본 발명에 따르면 항균 활성, 항염증 활성, 항알러지 활성 등을 나타내는 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등이 함침된, 기능성 생리대를 제공할 수 있다. As described above, according to the present invention, a functional sanitary napkin impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1 exhibiting antibacterial activity, anti-inflammatory activity, anti-allergic activity and the like can be provided.
본 발명의 기능성 생리대는 항균 활성, 항염증 활성, 항알러지 활성 등을 나타내는 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등이 함침됨으로써, 병원균 등의 세균에 인체 감염을 예방할 수 있는 효과를 가지고 또한 생리혈 등 분비물에 의한 피부 자극, 피부 습진, 피부 염증 등을 예방할 수 있는 효과를 가진다. The functional sanitary napkin of the present invention is impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1, which exhibits antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., and thus has an effect of preventing human infection from bacteria such as pathogens. It has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.
도 1은 본 발명의 바람직한 실시예에 따른 생리대의 사시도이다.1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention.
도 2는 본 발명의 바람직한 실시예에 따른 생리대의 분리 사시도이다.2 is an exploded perspective view of the sanitary napkin according to the preferred embodiment of the present invention.
도 3은 본 발명의 다른 바람직한 실시예에 따른 생리대의 사사도이다.3 is a perspective view of a sanitary napkin according to another preferred embodiment of the present invention.
이하 본 발명을 첨부된 도면을 참조하여 바람직한 실시예를 설명한다. 그러나 본 발명의 범위가 이러한 실시예에 한정되는 것은 아니다.Hereinafter, exemplary embodiments will be described with reference to the accompanying drawings. However, the scope of the present invention is not limited to these examples.
도 1은 본 발명의 바람직한 실시예에 따른 생리대의 사시도이고, 도 2는 본 발명의 바람직한 실시예에 따른 생리대의 분리 사시도이다.1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention, Figure 2 is an exploded perspective view of the sanitary napkin according to a preferred embodiment of the present invention.
본 발명은 항균 생리대는 크게 내부시트(100)와 외부시트(300) 그리고 그 사이에 게재되는 흡수부재(200)로 구성된다.In the present invention, the antibacterial sanitary napkin is largely composed of an inner sheet 100 and an outer sheet 300 and an absorbing member 200 disposed therebetween.
내부시트(100)는 생리혈 등 분비물이 투과될 수 있는 재질과 구조를 지니며, 구체적으로 1겹 이상의 직물이나 부직포로 구성될 수 있다. 이러한 직물이나 부직포를 구성하는 섬유는 특별한 제한 없이 합성섬유 또는 천연섬유 모두 사용될 수 있으며, 합성섬유라면, 나일론, 폴리비닐알코올(PVA) 섬유, 폴리에스테르 섬유, 폴리아크릴 섬유, 폴리아미드 섬유, 폴리우레탄 섬유, 폴리아크릴로니트릴 섬유, 폴리프로필렌 섬유, 폴리에틸렌 섬유 등이 제한 없이 모두 사용될 수 있고, 천연섬유라면 면 섬유, 코이어(Coier) 등의 종자 섬유, 마닐라삼이나 사이잘삼 등의 엽맥 섬유, 아마, 모시풀, 삼 등의 인피 섬유(靭皮纖維), 양모, 산양모 등의 수모 섬유, 가잠견, 야잠견 등의 견 섬유 등이 제한 없이 사용될 수 있다. 바람직하게는 인체에 대한 자극성을 최소화하기 위하여 면직물 등 천연섬유 재질의 직물을 사용하는 경우이다.The inner sheet 100 has a material and structure through which secretion, such as menstrual blood, can pass, and may be specifically composed of one or more layers of fabrics or nonwoven fabrics. The fibers constituting the woven or nonwoven fabric can be used both synthetic fibers and natural fibers without particular limitation, if synthetic fibers, nylon, polyvinyl alcohol (PVA) fibers, polyester fibers, polyacrylic fibers, polyamide fibers, polyurethane Fibers, polyacrylonitrile fibers, polypropylene fibers, polyethylene fibers and the like can all be used without limitation, and if natural fibers, cotton fibers, seed fibers such as Coier, leaf vein fibers such as manila hemp and sisal hemp, flax , Bast fibers such as ramie grass, hemp, wool fibers such as wool, goat wool, silk fibers such as gaze dog, and night sleep dog can be used without limitation. Preferably, in order to minimize the irritation to the human body when using a fabric made of natural fibers, such as cotton fabrics.
내부시트(100)는 인체와 접하는 부재로 이 내부시트(100)에 흡수되거나 이 내부시트(100)를 투과하는 생리혈 등 분비물에 의해 피부 자극, 피부 습진, 피부 염증 등이 발생할 수 있고 병원균을 비롯한 각종 세균이 증식할 수 있으므로, 이러한 피부 자극 등을 방지하고 각종 세균의 증식을 억제하기 위하여, 아래의 실험예에서 확인되는 바와 같이, 항균 활성, 항염증 활성, 항알러지 활성 등이 확인된 락토바실러스 플란타럼 nF1 등의 유산균 배양물이나 그것의 추출액, 그것의 농축액, 그것의 희석액, 또는 물, 에탄올 등을 분산매나 용매로 한 그것의 현탁액이나 용액을 내부시트(100)에 함침시켜 항균 기능, 항염증 활성, 항알러지 등을 가지도록 할 수 있다.The inner sheet 100 is a member in contact with the human body may be caused skin irritation, skin eczema, skin inflammation, etc. by secretions such as menstrual blood absorbed in the inner sheet 100 or penetrating the inner sheet 100, including pathogens Since various bacteria can proliferate, in order to prevent such skin irritation and suppress the growth of various bacteria, Lactobacillus has been confirmed antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., as confirmed in the experimental example below Lactobacillus cultures such as plantarum nF1, its extracts, its concentrates, its dilutions, or its suspensions or solutions using a dispersion medium or a solvent as water or ethanol are impregnated into the inner sheet 100 for antibacterial function, You can have anti-inflammatory activity, anti-allergy, etc.
이때 함침은 내부시트(100)를, 상기 락토바실러스 플란타럼 nF1 등의 유산균 배양물의 희석액 등에, 상온에서, 적정 시간 바람직하게는 12시간 이상, 더 바람직하게는 24시간 이상 침지시켜 이루어질 수 있다. 침지 후에는 함침된, 상기 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등이 안정화되도록 하고 또한 피부에 자극성이나 독성을 줄 수 있는 용매를 제거하기 위하여 예컨대 40℃ 내지 50℃ 범위의 온도에서 열풍건조시키는 것이 바람직할 수 있다.At this time, the impregnation may be made by immersing the inner sheet 100 in a diluent of a lactic acid bacterium culture such as Lactobacillus plantarum nF1 at room temperature, preferably for at least 12 hours, more preferably at least 24 hours. After soaking, the lactic acid bacteria cultures such as Lactobacillus plantarum nF1, which are impregnated, are stabilized and hot air dried at a temperature ranging from 40 ° C. to 50 ° C., for example, to remove solvents that may cause irritation or toxicity to the skin. It may be desirable to.
한편 당업계에는 피부 자극성을 완화시킬 수 있는 다양한 천연물 소재들이 제안되어 있다. 그러한 천연물 소재로는 항염증 활성, 항알러지 활성, 또는 이 둘의 활성을 함께 가지는 식물 추출물을 들 수 있는데, 구체적으로 때죽나무(Styrax japonica) 추출물, 홀아비꽃대(Chloranthus japonicus) 추출물, 나한송(Podocarpus macrophyllus) 추출물, 조록나무(Distylium racemosom) 추출물, 진달래(Rhododendron mucronulatum), 시로미(Empetrum nigrum) 추출물, 네가래(Marsilea quadrifolia) 추출물, 솜양지꽃(Potentilla discolor) 추출물, 풀고사리(Gleichenia japonica) 추출물, 개승마(Cimicifuga acerina) 추출물, 진귤(Citrus sunki) 과피 추출물, 고사리삼(Sceptridium ternatum) 추출물, 백기생(Korthalsella japonica) 추출물 등이 그러한 식물 추출물에 속한다. 이러한 천연물 소재를 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등을 내부시트(100)에 함침시킬 때 함께 함침시키거나 단독으로 함침시켜 피부 자극성, 피부 트러블 완화 효과의 부여나 그러한 효과의 상승·보강을 꾀할 수 있다.Meanwhile, various natural materials have been proposed in the art to alleviate skin irritation. Such natural materials include plant extracts having anti-inflammatory activity, anti-allergic activity, or both, specifically, Styrax japonica extract, Chloranthus japonicus ) extract, Podocarpus macrophyllus extract, Distylium racemosom extract, Rhododendron mucronulatum , Empetrum nigrum extract, Marsilea quadrifolia extract, Potentilla discolor extract, Gleichenia japonica extract, Cimicifuga acerina extract, Citrus sunki rind extract, Sceptridium ternatum extract and Korthalsella japonica extract are among such plant extracts. When impregnating these natural materials with lactic acid bacteria cultures such as Lactobacillus plantarum nF1 to the inner sheet 100, or impregnated alone, imparting skin irritation, skin trouble relieving effect, or enhancing or enhancing such effects. Can be designed.
상기 추출물을 함침시킬 때, 여과를 거치거나 거치지 않고 추출액 상태의 추출물을 사용하여, 상기 내피시트(100)를 이들 천연물 추출액에 상온에서 일정 시간 예컨대 12시간 이상이나 24시간 이상으로 침지시킴으로써, 내피시트(100)에 피부 자극 완화 등의 기능성을 부과할 수 있다. 물, 에탄올 이외의, 피부 자극성을 가질 수 있는 추출용매는 함침 시 그 용매가 내피시트(100)에 잔류하여 오히려 그 잔류 용매가 피부 자극성을 일으킬 수 있으므로, 함침된 내부시트(100)를 열풍건조 등 당업게에 공지된 방식으로 건조시켜 잔류 용매를 제거하거나, 물, 에탄올 이외의 추출용매로 얻어진 추출물을 사용할 경우는, 추출 후 감압농축, 동결건조, 진공건조, 열풍건조, 분무건조 등 당업계에 공지된 방식으로 추출 용매를 제거하여 분말상의 추출물을 얻고 그 분말상의 추출물을 물이나 에탄올, 특히 에탄올에 용해시켜 사용함으로써 추출 용매에 의한 피부 자극성 문제를 회피할 수도 있다.When the extract is impregnated, endothelial sheet by immersing the endothelial sheet 100 in these natural product extracts at a constant time, such as 12 hours or 24 hours or more at room temperature, using an extract in the extract state with or without filtration. Functionality such as skin irritation relief can be imparted to (100). In addition to water and ethanol, the extraction solvent which may have skin irritation may be a solvent remaining in the endothelial sheet 100 when impregnated, and the residual solvent may cause skin irritation, so that the impregnated inner sheet 100 may be hot air dried. Drying is carried out in a manner known in the art to remove residual solvents, or when using an extract obtained with an extraction solvent other than water and ethanol, it is concentrated in the art after extraction, freeze drying, vacuum drying, hot air drying, spray drying, etc. It is also possible to avoid the skin irritation problem caused by the extraction solvent by removing the extraction solvent in a manner known in the present invention to obtain a powdered extract and dissolving the powdered extract in water or ethanol, especially ethanol.
본 발명의 기능성 생리대에서, 흡수부재(200)는 생리혈 등 분비물을 흡수하기 위한 것으로 흡수성과 보수성(保水性)이 우수해야 하므로, 흡수부재(200)는 이를 고려하여 면 섬유나 양모, 산양모 등의 수모 섬유 등을 솜 형태로 하여 내용물로 구성하고 부직포 등을 외피로 구성하여 이루어질 수 있다. 바람직하게는 생리대에 통상적으로 사용되어온 폴리아크릴산 나트륨 등과 같은 고분자 흡수체를 내용물로 하여 이루어질 수 있다. 폴리아크릴산 나트륨은 당업계에 자신의 무게 200배 정도의 수분을 흡수할 수 있는 흡수력을 가진다고 알려져 있는 소재이다. In the functional sanitary napkin of the present invention, the absorbent member 200 is to absorb secretions such as menstrual blood, so that the absorbency and water retention should be excellent, so that the absorbent member 200 may consider cotton fiber or wool, goat's wool, etc. It can be made of the hair wool fiber, etc. in the form of cotton and the composition of the nonwoven fabric and the like. Preferably, the content may be a polymer absorbent such as sodium polyacrylate, which has been conventionally used in sanitary napkins. Sodium polyacrylate is a material known in the art to have an absorption ability to absorb about 200 times its weight.
상기 흡수부재(200)는 생리혈 등 분비물이 흡수되는 부재이므로 병원균 등 세균이 증식할 수 있다. 따라서 이를 억제하기 위하여 내부시트(100)와 마찬가지로, 항균 활성 등이 확인된 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등을 함침시켜 항균 기능을 가지도록 하는 것이 바람직하다.Since the absorbing member 200 is a member for absorbing secretions such as menstrual blood, bacteria such as pathogens may proliferate. Therefore, in order to suppress this, it is preferable to impregnate the culture of lactic acid bacteria such as Lactobacillus plantarum nF1, such as the antibacterial activity is confirmed, such as the inner sheet 100 to have an antibacterial function.
본 발명의 기능성 생리대에서 흡수부재(200)의 외측에는 외부시트(300)가 위치하는데, 외부시트(300)는 피부와 닿지 않고 속옷에 접하는 부재로 생리혈 등의 분비물의 누출을 방지할 수 있어야 하므로, 방수성 소재, 예컨대 폴리에틸렌 필름 등의 재질로 제작되어 진다. 더불어 상기 외부시트(300)의 외면에는 접착재와 박리지로 접착 부재를 형성시켜 속옷에 부착·고정되도록 할 수 있다. In the functional sanitary napkin of the present invention, the outer sheet 300 is located on the outside of the absorbent member 200. Since the outer sheet 300 is a member in contact with the underwear without touching the skin, it should be able to prevent the leakage of secretion such as menstrual blood. It is made of a waterproof material such as polyethylene film. In addition, the outer surface of the outer sheet 300 can be attached to and fixed to the underwear by forming an adhesive member with an adhesive and release paper.
본 발명의 기능성 생리대는 최종적으로는 내부시트(100)와 외부시트(300) 사이에 흡착부재(200)를 게재시키고 내부시트(100)와 외부시트(300)의 주변부를 박음질, 초음파 융착 또는 열융착에 의해 결합시킴으로써 이루어지게 된다.In the functional sanitary napkin of the present invention, the adsorption member 200 is finally placed between the inner sheet 100 and the outer sheet 300, and the periphery of the inner sheet 100 and the outer sheet 300 is stitched, ultrasonically fused or heated. It is made by bonding by fusion.
또한 본 발명의 기능성 생리대는 도 3에 도시된 바와 같이 여성에 따라 생리혈 등 분비물이 많은 경우에 추가로 사용하기 위한 보조 흡착부재(400)를 더 포함하여 구성될 수도 있다. In addition, the functional sanitary napkin of the present invention may further comprise an auxiliary adsorption member 400 for further use in the case of a large amount of secretion, such as menstrual blood, depending on the woman as shown in FIG.
보조 흡착부재(400)도 흡착부재(200)와 동일하게 면 섬유나 양모, 산양모 등의 수모 섬유 등을 솜 형태로 하여 내용물로 하거나, 폴리아크릴산 나트륨 등과 같은 고분자 흡수체를 내용물로 할 수 있다. 흡착부재(200)와 마찬가지로 부직포 등으로 외피를 구성할 수 있다. Similarly to the adsorption member 200, the auxiliary adsorption member 400 may be made of cotton fibers, wool fibers such as wool, goat wool, or the like in the form of cotton, or a polymer absorbent such as sodium polyacrylate. Like the adsorption member 200, the outer shell may be made of a nonwoven fabric or the like.
본 발명의 기능성 생리대가 보조 흡착부재(400)를 추가로 포함할 경우, 내부시트(100)에는 절개부(101)를 형성시켜 상기 보조 흡착부재(100) 탈착되도록 삽입시킬 수 있다. When the functional sanitary napkin of the present invention further includes the auxiliary adsorption member 400, the inner sheet 100 may be inserted to detach the auxiliary adsorption member 100 by forming a cutout 101.
또한 보조 흡착부재(400)도 항균성을 갖도록 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등을 함침시키는 것이 바람직할 수 있다.In addition, it may be preferable to impregnate the lactic acid bacteria culture such as Lactobacillus plantarum nF1 so that the auxiliary adsorption member 400 also has antibacterial properties.
이상과 같이 본 발명의 기능성 생리대를 기본 구성요소인 내부시트(100), 흡수부재(200) 및 외부시트(300) 중심으로 설명하였지만, 본 발명의 기능성 생리대는 내부시트(100) 및/또는 흡수부재(200)에 락토바실러스 플란타럼 nF1 등의 유산균 배양물 등을 함침시켜 항균 활성, 항염증 활성, 항알러지 등을 가지도록 한 것에 특징이 있으며, 이들의 특징을 가지는 한 여타의 구성요소를 부가·변경한 생리대도 본 발명의 범위에 포함되는 것으로 이해되어야 한다. As described above, the functional sanitary napkin of the present invention has been described based on the inner sheet 100, the absorbent member 200, and the outer sheet 300, which are basic components, but the functional sanitary napkin of the present invention is the inner sheet 100 and / or absorbent. The member 200 is impregnated with a culture of lactic acid bacteria such as Lactobacillus plantarum nF1 to have antimicrobial activity, anti-inflammatory activity, anti-allergy, and the like. It is to be understood that added and modified sanitary napkins are also included in the scope of the present invention.
<< 실험예Experimental Example > > 락토바실러스Lactobacillus 플란타룸Planta Room nF1nF1 배양물 등의 항균 활성, 항염 활성 및 항알러지 활성 실험 Antimicrobial, Anti-inflammatory and Anti-allergic Activities of Cultures
<< 실험예Experimental Example 1>  1> 락토바실러스Lactobacillus 플란타룸Planta Room nF1nF1 등의 항균 활성 실험 Antimicrobial activity test
<실험예 1-1> 락토바실러스 플란타럼 nF1 배양물 등의 준비 Experimental Example 1-1 Lactobacillus Plantarum Preparation of nF1 Culture, etc.
MRS(DeMan, Rogosa, and Sharpe) broth(Difco Lactobacilli MRS Broth, Japan Becton, Dickinson & Co.)에 유산균을 초기 균체 농도 1×104cfu/mL로 접종하고, 락토바실러스 플란타럼 nF1(기탁번호 NITE P-1462)("nF1"), 락토바실러스 플란타럼 SNK12(기탁번호: NITE P-1445)("SNK12"), 락토바실러스 플란타룸 KH3(기탁번호 NITE AP-1476)("KH3")는 32℃에서, 엔테로코커스 패칼리스 KH2(수탁번호 NITE P-1444)("KH2")에 대해서는 37℃, 락토바실러스 브레비스(수탁번호 FERP BP-4693)("Labre")에 대해서는 31∼32℃, 락토코커스 락티스 아종 크레모리스 CF4(수탁번호 FERM P-20848)("CF4")에 대해서는 30℃에서, 2일 동안 배양하였다. Lactobacillus was inoculated at MRS (DeMan, Rogosa, and Sharpe) broth (Difco Lactobacilli MRS Broth, Japan Becton, Dickinson & Co.) at an initial cell concentration of 1 × 10 4 cfu / mL, and Lactobacillus plantarum nF1 (Accession No. NITE P-1462) ("nF1"), Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445) ("SNK12"), Lactobacillus plantarum KH3 (Accession Number NITE AP-1476) ("KH3" ) At 32 ° C., 37 ° C. for Enterococcus faecalis KH2 (Accession No. NITE P-1444) (“KH2”), and 31 to 32 for Lactobacillus brevis (Accession No. FERP BP-4693) (“Labre”). C., Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848) (“CF4”) was incubated at 30 ° C. for 2 days.
배양액은 멸균기를 이용 121℃에서 20분 동안 멸균하고 감압농축과 동결건조시킨 후 냉장보관하면서 실험에 사용하였다.The culture was sterilized at 121 ° C. for 20 minutes using a sterilizer, concentrated under reduced pressure and lyophilized, and used for experiments while refrigerated.
<실험예 1-2> 평판배지 확산법에 의한 항균 활성 실험 <Experimental Example 1-2> Antimicrobial activity experiment by plate medium diffusion method
항균 활성을 평판배지 확산법(Food. Chem. Toxicol. 40(4): 535-543, 2002)에 의한 측정하였다. 실험에 사용할 디스크는 시료(상기 <실험예 1-1>의 배양물)는 1 mg/ml 농도로 에탄올에 녹인 후 상기 시료 용액을 디스크(Whatman No.5)에 천천히 흡수시킨 후, 용매를 완전히 증발시켜 제조하였다. 제조된 디스크를 각 시험균이 도말된 평판배지에 밀착시키고 아래 [표 1]의 배양온도에서 배양한 후 디스크 주변에 형성된 생육 저해환(clear zone)의 크기(mm)를 측정하였다. 결과를 [표 2]에 나타내었다.Antimicrobial activity was measured by plate medium diffusion method (Food. Chem. Toxicol. 40 (4): 535-543, 2002). The disk to be used for the experiment was dissolved in ethanol at a concentration of 1 mg / ml of the sample (culture of <Experimental Example 1-1>), and then slowly absorbed the sample solution into the disk (Whatman No. 5), and then completely removed the solvent. Prepared by evaporation. The prepared disk was adhered to the plate medium plated with each test bacteria and incubated at the incubation temperature of the following [Table 1], and then the size (mm) of growth zones (clear zone) formed around the disk was measured. The results are shown in [Table 2].
균주Strain 배양 조건Culture condition
Bacillus subtilis KCTC 1021 Bacillus subtilis KCTC 1021 Nutrient media, 30℃, AerobicNutrient media, 30 ℃, Aerobic
Staphylococcus aureus KCTC 1927 Staphylococcus aureus KCTC 1927 Nutrient media, 37℃, AerobicNutrient media, 37 ℃, Aerobic
Strptococcus mutans KCTC 3300 Strptococcus mutans KCTC 3300 Nutrient media, 37℃, AerobicNutrient media, 37 ℃, Aerobic
Escherichia coli KCTC 1039 Esherichia coli KCTC 1039 Nutrient media, 37℃, AerobicNutrient media, 37 ℃, Aerobic
Gardnerella vaginalis KCTC 5096 Gardnerella vaginalis KCTC 5096 Nutrient media, 37℃, AnaerobicNutrient media, 37 ℃, Anaerobic
생육 저해환의 크기(mm)Size of growth inhibiting ring (mm)
균주Strain nF1nF1 SNK12SNK12 KH3KH3 KH2KH2 LabreLabre CF4CF4
B. B. subtilissubtilis -- 6.506.50 10.5010.50 8.258.25 4.254.25 --
S. S. aureusaureus 8.508.50 8.08.0 6.506.50 -- 8.08.0 5.05.0
S. S. mutansmutans 11.011.0 9.259.25 6.506.50 8.508.50 4.504.50 8.258.25
E. E. colicoli 4.04.0 5.05.0 8.08.0 8.258.25 9.09.0 --
G. G. vaginalisvaginalis 14.5014.50 9.259.25 5.05.0 7.257.25 -- 6.06.0
* - : 항균 활성 없음*-: No antimicrobial activity
상기 [표 2]의 결과는 유산균 nF1 배양물이 B. subtilis에 대해서 항균 활성을 보이지 않는 등 몇 가지 경우를 제외하고 상기 <실험예 1-1>의 유산균 배양물이 항균 대상 대부분의 미생물에 대해서 항균 활성을 보였다. The results of Table 2 show that the lactic acid bacteria culture of <Experimental Example 1-1> was the most effective against the microorganisms of the microorganisms except for some cases, such as the lactic acid bacteria nF1 culture did not show antimicrobial activity against B. subtilis . It showed antimicrobial activity.
<< 실험예Experimental Example 2>  2> 항염 활성 실험 - NO assayAnti-inflammatory activity test-NO assay
마우스 대식세포주인 RAW264.7 cell를 LPS(Lipopolysacharide)로 자극시킨 세포 모델을 사용하여 항염 활성을 평가하였다. 구체적으로 상기 마우스 대식세포를 48 well plate에 5×104cells/well의 세포 수로 분주하고 37℃, 5% CO2의 조건에서 24시간 동안 배양하였다. 시료 100㎍/ml와 LPS 1㎍/ml를 동시 처리하고 24시간 동안 배양하였다. 배양 후 세포배양 상등액 50㎕와 Griess 시약[1% (w/v) sulfanilamide, 0.1% (w/v) naphylethylenediamine in 2.5% (v/v) phosphoric acid] 50㎕를 혼합하여 10분간 상온에서 반응시킨 후 540nm에서 흡광도를 측정하여 ELISA 측정을 통해 대조군 대비 NO 생성 억제능을 측정하였다. 생성된 NO의 양은 sodium nitrite(NaNO2)를 standard로 비교하였다.Anti-inflammatory activity was evaluated using a cell model in which RAW264.7 cells, a mouse macrophage line, were stimulated with Lipopolysacharide (LPS). Specifically, the mouse macrophage cells were dispensed in a 48 well plate with a cell number of 5 × 10 4 cells / well and incubated for 24 hours at 37 ° C. and 5% CO 2 . 100 μg / ml sample and 1 μg / ml LPS were co-treated and incubated for 24 hours. After incubation, 50 μl of cell culture supernatant and 50 μl of Griess reagent [1% (w / v) sulfanilamide, 0.1% (w / v) naphylethylenediamine in 2.5% (v / v) phosphoric acid] were mixed and reacted at room temperature for 10 minutes. After measuring the absorbance at 540nm was measured the NO production inhibitory ability compared to the control by ELISA measurement. The amount of NO produced was compared with sodium nitrite (NaNO 2 ) as standard.
결과를 아래의 [표 3]에 나타내었다.The results are shown in Table 3 below.
NO 생성 억제능(%)과 세포생존율(%)NO production inhibitory activity (%) and cell survival rate (%)
균주Strain nF1nF1 SNK12SNK12 KH3KH3 KH2KH2 LabreLabre CF4CF4
NO 생성 억제능NO production inhibitory ability 38.43±7.6438.43 ± 7.64 28.56±3.2728.56 ± 3.27 56.32±5.2756.32 ± 5.27 43.54±4.8643.54 ± 4.86 62.28±5.6262.28 ± 5.62 48.60±5.3848.60 ± 5.38
세포 생존율Cell viability 94.28±5.2794.28 ± 5.27 102.48±4.45102.48 ± 4.45 106.32±3.29106.32 ± 3.29 98.27±4.4998.27 ± 4.49 102.60±11.08102.60 ± 11.08 97.52±6.2497.52 ± 6.24
상기 [표 2]의 결과는 NO 생성 억제 활성에 차이를 보이지만 상기 <실험예 1-1>의 유산균 배양물이 LPS로 자극된 마우스 대식세포주에 대해서 대체로 NO 생성 억제 활성을 나타냄을 보여준다.The results of Table 2 show a difference in NO production inhibitory activity, but shows that the lactic acid bacteria culture of Experimental Example 1-1 generally showed NO production inhibitory activity against LPS-stimulated mouse macrophage lines.
한편 세포생존율은 MTT법으로 측정하였다. 구체적으로 48 well plate 내에 남아있는 배지를 제거하고 5mg/㎖ MTT solution이 10% 포함된 serum free 배지를 well당 각각 100㎕씩 넣고 37℃, 5% CO2 incubator에 넣어 2시간 동안 반응시킨 후 배지를 제거하고 DMSO를 100㎕/well로 넣어 Shaker에서 15분간 용해시켜 ELlSA reader를 이용해 540nm에서 흡광도를 측정하여 세포 생존율을 구하였다. 결과를 상기 [표 3]에 함께 나타내었다. Cell viability was measured by the MTT method. Specifically, the remaining medium in the 48 well plate was removed, and 100 μl of serum free medium containing 10% of 5 mg / ml MTT solution was added to each well in 37 ° C. and 5% CO 2 incubator, followed by reaction for 2 hours. Removed and dissolved DMSO in 100μl / well for 15 minutes in the shaker and measured the absorbance at 540nm using ELlSA reader to determine the cell viability. The results are shown in Table 3 together.
상기 [표 3]에서 확인되듯이, 상기 <실험예 1-1>의 유산균 배양물은 특별히 세포독성을 나타내지 않음을 알 수 있으며, 또한 상기 NO 생성 억제 결과가 세포독성에 의한 것이 아님을 알 수 있다. As confirmed in [Table 3], it can be seen that the lactic acid bacteria cultures of <Experimental Example 1-1> do not exhibit cytotoxicity in particular, and the NO production suppression result is not due to cytotoxicity. have.
<< 실험예Experimental Example 3>  3> 항알러지Anti-allergy 활성 실험 - β- Activity experiment-β- hexosaminidasehexosaminidase assay assay
항알러지 활성을 β-hexosaminidase assay를 통하여 평가하였다.Anti-allergic activity was assessed by β-hexosaminidase assay.
β-hexosaminidase assay 평가를 위해, Rat basophilic leukemia 셀 라인인 RBL-2H3 세포주를 2×105 세포/well로 24 웰 플레이트에 분주하고 0.5㎍/㎖의 마우스 단일클론 IgE를 처리하여 37℃, 5% CO2 조건에서 하룻밤 배양하여 세포를 감작하였다. 감작된 세포를 siraganian buffer(25mM PIPES, 119mM NaCl, 5mM KCl, 0.4mM MgCl2, 40mM NaOH, pH 7.2)로 2회 세척하고 160㎕ PIPES buffer(25mM PIPES, 119mM NaCl, 5mM KCl, 1mM CaCl2, 0.4mM MgCl2, 40mM NaOH, 5.6mM glucose, 0.1% BSA)를 첨가하여 37℃에서 10분 동안 배양하였다. 그 후, 시료 100㎍/ml를 첨가하여 20분 동안 반응한 후, DNP-HSA(Dinitrophenyl-Human Serum Albumin, 1㎍/㎖) 20㎕를 항원으로 처리하여 10분 동안 37℃에서 배양하여 탈과립을 유도하였다. 다음 96 웰 플레이트에 반응물의 상등액 20㎕를 넣고 20㎕ 기질 1mM P-니트로페닐-아세틸-β-D-글루코사미니드를 넣은 후 37℃에서 1시간 반응시켰다. stop solution(0.1M NaHCO3, O.1M Na2CO3)를 넣고 반응을 종결시킨 후 405nm 파장대에서 ELISA 리더로 흡광도를 측정하였다. 결과를 시료 무처리군 대비 백분율로 [표 4]에 나타내었다.To evaluate the β-hexosaminidase assay, a rat basophilic leukemia cell line RBL-2H3 cell line was dispensed into 2 wells at 24 × plates at 2 × 10 5 cells / well and treated with 0.5 μg / ml mouse monoclonal IgE at 37 ° C., 5%. Cells were sensitized by incubating overnight in CO 2 conditions. The sensitized cells were washed twice with siraganian buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 40 mM NaOH, pH 7.2) and 160 μl PIPES buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 0.4 mM MgCl 2 , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA) was added and incubated at 37 ° C. for 10 minutes. Thereafter, 100 µg / ml of the sample was added to react for 20 minutes, and 20 µl of DNP-HSA (Dinitrophenyl-Human Serum Albumin, 1 µg / ml) was treated with an antigen and incubated at 37 ° C. for 10 minutes to remove degranulated particles. Induced. Next, 20 µl of the supernatant of the reactants was put into a 96 well plate, and 20 µm of substrate 1 mM P-nitrophenyl-acetyl-β-D-glucosamide was added and reacted at 37 ° C. for 1 hour. A stop solution (0.1 M NaHCO 3 , 0.1 M Na 2 CO 3 ) was added thereto, and the reaction was terminated. The absorbance was measured using an ELISA reader at a wavelength of 405 nm. The results are shown in [Table 4] as a percentage compared to the sample untreated group.
탈과립 억제 활성(β-hexosaminidase 유리 억제 활성)(%)Degranulation inhibitory activity (β-hexosaminidase free inhibitory activity) (%)
균주Strain nF1nF1 SNK12SNK12 KH3KH3 KH2KH2 LabreLabre CF4CF4
탈과립억제 활성Degranulation inhibitory activity 42.57±4.6942.57 ± 4.69 52.26±9.3652.26 ± 9.36 46.28±11.8246.28 ± 11.82 48.48±12.9248.48 ± 12.92 36.80±5.2736.80 ± 5.27 64.28±8.2964.28 ± 8.29
상기 [표 4]의 결과는 활성에 차이를 보이지만 상기 <실험예 1-1>의 유산균 배양물이 전체적으로 탈과립 억제 활성을 보여 항알러지 활성을 가짐을 보여준다.The results of Table 4 show a difference in activity, but shows that the lactic acid bacteria culture of <Experimental Example 1-1> showed anti-granular inhibitory activity as a whole and had anti-allergic activity.
[부호의 설명][Description of the code]
100: 내부시트100: inner sheet
200: 흡수부재200: absorbing member
300: 외부시트300: outer sheet
400: 보조 흡수부재400: auxiliary absorbing member

Claims (5)

  1. (i) 주변부가 서로 접합된 내부시트와 외부시트, 및 (i) inner and outer sheets with periphery joined together;
    (ii) 그 사이에 게재된 흡수부재를 포함하여 구성되되, (ii) including an absorbent member interposed therebetween,
    상기 내부시트 및 흡수부재 중 어느 하나에, 아래 (a) 내지 (f)의 유산균 배양물 중에서 선택된 어느 하나의 배양물이나 그 배양물을 포함하는 용액이 함침된 것을 특징으로 하는 기능성 생리대:Functional sanitary napkins, characterized in that any one of the inner sheet and the absorbent member is impregnated with any one culture selected from the culture of lactic acid bacteria (a) to (f) or a solution containing the culture:
    (a) 락토바실러스 플란타럼 nF1(기탁번호 NITE P-1462), (a) Lactobacillus plantarum nF1 (Accession No. NITE P-1462),
    (b) 락토바실러스 플란타럼 SNK12(기탁번호: NITE P-1445), (b) Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445),
    (c) 락토바실러스 플란타룸 KH3(기탁번호 NITE AP-1476),(c) Lactobacillus plantarum KH3 (Accession No. NITE AP-1476),
    (d) 엔테로코커스 패칼리스 KH2(수탁번호 NITE P-1444),(d) Enterococcus faecalis KH2 (Accession No. NITE P-1444),
    (e) 락토바실러스 브레비스(수탁번호 FERP BP-4693), 및(e) Lactobacillus brevis (Accession No. FERP BP-4693), and
    (f) 락토코커스 락티스 아종 크레모리스 CF4(수탁번호 FERM P-20848).(f) Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848).
  2. 제1항에 있어서,The method of claim 1,
    상기 유산균 배양물은 락토바실러스 플란타럼 nF1(기탁번호 NITE P-1462) 배양물인 것을 특징으로 하는 기능성 생리대.The lactic acid bacteria culture is a functional sanitary napkin, characterized in that the Lactobacillus plantarum nF1 (Accession Number NITE P-1462) culture.
  3. 제1항에 있어서,The method of claim 1,
    상기 기능성 생리대는 보조 흡수부재를 추가로 포함하고, 상기 내부시트에는 상기 보조 흡수부재가 탈착적으로 삽입될 수 있는 절개부가 형성되어 있는 것을 특징으로 하는 기능성 생리대.The functional sanitary napkin further comprises an auxiliary absorbing member, wherein the inner sheet is a functional sanitary napkin, characterized in that the incision is formed to be inserted into the secondary absorbent member detachably.
  4. 제3항에 있어서,The method of claim 3,
    상기 보조 흡수부재에는 아래 (a) 내지 (f)의 유산균 배양물 중에서 선택된 어느 하나의 배양물이나 그 배양물을 포함하는 용액이 함침된 것을 특징으로 하는 기능성 생리대:Functional auxiliary sanitary napkin is characterized in that the auxiliary absorbing member is impregnated with any one culture selected from the culture of lactic acid bacteria (a) to (f) or a solution containing the culture:
    (a) 락토바실러스 플란타럼 nF1(기탁번호 NITE P-1462), (a) Lactobacillus plantarum nF1 (Accession No. NITE P-1462),
    (b) 락토바실러스 플란타럼 SNK12(기탁번호: NITE P-1445), (b) Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445),
    (c) 락토바실러스 플란타룸 KH3(기탁번호 NITE AP-1476),(c) Lactobacillus plantarum KH3 (Accession No. NITE AP-1476),
    (d) 엔테로코커스 패칼리스 KH2(수탁번호 NITE P-1444),(d) Enterococcus faecalis KH2 (Accession No. NITE P-1444),
    (e) 락토바실러스 브레비스(수탁번호 FERP BP-4693), 및(e) Lactobacillus brevis (Accession No. FERP BP-4693), and
    (f) 락토코커스 락티스 아종 크레모리스 CF4(수탁번호 FERM P-20848).(f) Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848).
  5. 제4항에 있어서,The method of claim 4, wherein
    상기 유산균 배양물은 락토바실러스 플란타럼 nF1(기탁번호 NITE P-1462) 배양물인 것을 특징으로 하는 기능성 생리대.The lactic acid bacteria culture is a functional sanitary napkin, characterized in that the Lactobacillus plantarum nF1 (Accession Number NITE P-1462) culture.
PCT/KR2017/008163 2016-07-29 2017-07-28 Functional sanitary napkin WO2018021874A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0096967 2016-07-29
KR20160096967 2016-07-29

Publications (1)

Publication Number Publication Date
WO2018021874A1 true WO2018021874A1 (en) 2018-02-01

Family

ID=61017262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/008163 WO2018021874A1 (en) 2016-07-29 2017-07-28 Functional sanitary napkin

Country Status (2)

Country Link
KR (1) KR102087051B1 (en)
WO (1) WO2018021874A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111295B1 (en) 2018-02-05 2020-05-15 주식회사 만도 Apparatus and method for controlling vehicle based on redundant architecture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061201A1 (en) * 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products
KR20040101335A (en) * 2002-03-21 2004-12-02 비포단 에이/에스 Lactobacillus strains
KR20110010867A (en) * 2009-07-27 2011-02-08 이성기 A hygienic band
KR20140140387A (en) * 2013-05-29 2014-12-09 바이오제닉스코리아 주식회사 Nano-Sized Lactic Acid Bacteria from Kimchi
US20150209468A1 (en) * 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940001575B1 (en) * 1991-12-24 1994-02-25 주식회사 럭키 Disposable absorbent product composition comprising lactoferrin
SE9703669D0 (en) * 1997-10-08 1997-10-08 Moelnlycke Ab Articles and preparation comprising lactic acid bacteria
SE519648C2 (en) * 1998-03-06 2003-03-25 Essum Ab New strain of Lactobacillus plantarum
SE528382C2 (en) * 2004-10-05 2006-10-31 Probi Ab Probiotic lactobacillus strains for improved vaginal health

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061201A1 (en) * 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products
KR20040101335A (en) * 2002-03-21 2004-12-02 비포단 에이/에스 Lactobacillus strains
KR20110010867A (en) * 2009-07-27 2011-02-08 이성기 A hygienic band
KR20140140387A (en) * 2013-05-29 2014-12-09 바이오제닉스코리아 주식회사 Nano-Sized Lactic Acid Bacteria from Kimchi
US20150209468A1 (en) * 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism

Also Published As

Publication number Publication date
KR102087051B1 (en) 2020-03-10
KR20180013793A (en) 2018-02-07

Similar Documents

Publication Publication Date Title
KR102258914B1 (en) Antibiotic Mask
RU2212902C2 (en) Product and preparation containing lactic acid bacteria
AU780367B2 (en) Methods for inhibiting microbial infections associated with sanitary products
EP2081606B1 (en) Sanitary article comprising a microbe-inhibiting composition
DE69919518T2 (en) Lactobacillus strain
CN101678147A (en) Sanitary article comprising lactobacilli in a hydrophilic carrier
CN104382685B (en) A kind of preparation method of human vagina&#39;s probiotics-probio sheath
WO2018021874A1 (en) Functional sanitary napkin
US20100104615A1 (en) Absorbent article comprising lactic acid producing bacteria
CN110680855A (en) Vaginal expansion suppository containing probiotics and traditional Chinese medicine composition and preparation method thereof
CN107937324A (en) One plant of Lactobacillus crispatus and its application
EP1689452B1 (en) Absorbent article containing a skin-care agent
Demirezen et al. Cytologic findings in pap smears with Actinomyces-like organisms
CN110547915A (en) sanitary cotton product using probiotics and preparation method thereof
CN112175867B (en) Functional non-woven fabric based on inactivated lactic acid bacteria
RU2183963C2 (en) &#34;emulact&#34; ointment for treatment and prevention of inflammatory gynecological diseases and disbacteriosis
MXPA00003411A (en) Product and preparation containing lactic acid bacteria
Sasso et al. ADHESION OF PROBIOTIC LACTOBACILLI TO HUMAN VAGINAL CELLS IN PRESENCE OF THYMOL AND EUGENOL.
EP3319650A1 (en) Novel hygiene article
WO2011003370A2 (en) Inhibition of exoproteins using bacteria of the lactobacillus genus
MXPA00008161A (en) New agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17834815

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17834815

Country of ref document: EP

Kind code of ref document: A1